Long non-coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer

Jaime Villegas, Alexis Rivas, Rodolfo Ávila, Vincenzo Borgna, Lorena Lobos-Gonzales, Verónica Burzio, Constanza López, Reynaldo Gomez, Eduardo Landerer, Laura Velarde, L. O. Burzio

Resultado de la investigación: Article

Resumen

Bladder cancer (BC) is a heterogeneous disease with 70% of patients presenting superficial tumours and 30% presenting muscle-invading disease with a high risk of death associated to metastasis. The diagnosis is carried out by urine cytology, whith high specificity but low sensitivity, and cystoscopy, an expensive and unpleasant procedure. Carcinoma in situ and other high grade non-muscle-invasive tumors are treated by intravesical administration of BCG or other chemotherapeutic agents, while the indication for muscle-invasive disease is radical cystectomy. Human cells express a family of mitochondrial long non-coding RNAs (ncRNAs). One of these transcripts, the sense mitochondrial ncRNA or SncmtRNA, is expressed in normal proliferating cells and tumor cells but not in non-dividing cells. In addition, normal human proliferating cells express two antisense transcripts, ASncmtRNA-1 and ASncmtRNA-2. Strikingly however, the ASncmtRNAs are down-regulated in tumor cell lines as well as in tumor cells present in different types of human cancer, including BC. Therefore, the differential expression profile of these transcripts allows to detect cancer cells in biopsies and biological fluids. Down-regulation of the ASncmtRNAs seems to be an important hallmark of cancer and, hypothetically, may also represent a general vulnerability of cancer cells. Indeed, knock-down of the ASncmtRNAs using antisense oligonucleotides (ASO) exerts negative effects on cell proliferation and viability of bladder cancer cell lines representing a novel therapeutic strategy for this disease. We discuss recent advances on the use of the mitochondrial ncRNAs as targets for diagnostic and therapeutic protocols of BC and its potential use in the clinic.

Idioma originalEnglish
Páginas (desde-hasta)147-162
Número de páginas16
PublicaciónInternational Journal of Cancer Research and Prevention
Volumen7
N.º2
EstadoPublished - 2014

Huella dactilar

Long Noncoding RNA
Urinary Bladder Neoplasms
Neoplasms
Therapeutics
Intravesical Administration
Muscles
Untranslated RNA
Cystoscopy
mitochondrial RNA
Antisense Oligonucleotides
Cystectomy
Carcinoma in Situ
Mycobacterium bovis
Tumor Cell Line
Cell Biology
Cell Survival
Down-Regulation
Cell Proliferation
Urine
Neoplasm Metastasis

ASJC Scopus subject areas

  • Oncology
  • Social Psychology

Citar esto

Villegas, Jaime ; Rivas, Alexis ; Ávila, Rodolfo ; Borgna, Vincenzo ; Lobos-Gonzales, Lorena ; Burzio, Verónica ; López, Constanza ; Gomez, Reynaldo ; Landerer, Eduardo ; Velarde, Laura ; Burzio, L. O. / Long non-coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer. En: International Journal of Cancer Research and Prevention. 2014 ; Vol. 7, N.º 2. pp. 147-162.
@article{5d6214d52ebb45a68d6f729999bbc340,
title = "Long non-coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer",
abstract = "Bladder cancer (BC) is a heterogeneous disease with 70{\%} of patients presenting superficial tumours and 30{\%} presenting muscle-invading disease with a high risk of death associated to metastasis. The diagnosis is carried out by urine cytology, whith high specificity but low sensitivity, and cystoscopy, an expensive and unpleasant procedure. Carcinoma in situ and other high grade non-muscle-invasive tumors are treated by intravesical administration of BCG or other chemotherapeutic agents, while the indication for muscle-invasive disease is radical cystectomy. Human cells express a family of mitochondrial long non-coding RNAs (ncRNAs). One of these transcripts, the sense mitochondrial ncRNA or SncmtRNA, is expressed in normal proliferating cells and tumor cells but not in non-dividing cells. In addition, normal human proliferating cells express two antisense transcripts, ASncmtRNA-1 and ASncmtRNA-2. Strikingly however, the ASncmtRNAs are down-regulated in tumor cell lines as well as in tumor cells present in different types of human cancer, including BC. Therefore, the differential expression profile of these transcripts allows to detect cancer cells in biopsies and biological fluids. Down-regulation of the ASncmtRNAs seems to be an important hallmark of cancer and, hypothetically, may also represent a general vulnerability of cancer cells. Indeed, knock-down of the ASncmtRNAs using antisense oligonucleotides (ASO) exerts negative effects on cell proliferation and viability of bladder cancer cell lines representing a novel therapeutic strategy for this disease. We discuss recent advances on the use of the mitochondrial ncRNAs as targets for diagnostic and therapeutic protocols of BC and its potential use in the clinic.",
author = "Jaime Villegas and Alexis Rivas and Rodolfo {\'A}vila and Vincenzo Borgna and Lorena Lobos-Gonzales and Ver{\'o}nica Burzio and Constanza L{\'o}pez and Reynaldo Gomez and Eduardo Landerer and Laura Velarde and Burzio, {L. O.}",
year = "2014",
language = "English",
volume = "7",
pages = "147--162",
journal = "International Journal of Cancer Prevention",
issn = "1554-1134",
publisher = "Nova Science Publishers Inc",
number = "2",

}

Villegas, J, Rivas, A, Ávila, R, Borgna, V, Lobos-Gonzales, L, Burzio, V, López, C, Gomez, R, Landerer, E, Velarde, L & Burzio, LO 2014, 'Long non-coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer', International Journal of Cancer Research and Prevention, vol. 7, n.º 2, pp. 147-162.

Long non-coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer. / Villegas, Jaime; Rivas, Alexis; Ávila, Rodolfo; Borgna, Vincenzo; Lobos-Gonzales, Lorena; Burzio, Verónica; López, Constanza; Gomez, Reynaldo; Landerer, Eduardo; Velarde, Laura; Burzio, L. O.

En: International Journal of Cancer Research and Prevention, Vol. 7, N.º 2, 2014, p. 147-162.

Resultado de la investigación: Article

TY - JOUR

T1 - Long non-coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer

AU - Villegas, Jaime

AU - Rivas, Alexis

AU - Ávila, Rodolfo

AU - Borgna, Vincenzo

AU - Lobos-Gonzales, Lorena

AU - Burzio, Verónica

AU - López, Constanza

AU - Gomez, Reynaldo

AU - Landerer, Eduardo

AU - Velarde, Laura

AU - Burzio, L. O.

PY - 2014

Y1 - 2014

N2 - Bladder cancer (BC) is a heterogeneous disease with 70% of patients presenting superficial tumours and 30% presenting muscle-invading disease with a high risk of death associated to metastasis. The diagnosis is carried out by urine cytology, whith high specificity but low sensitivity, and cystoscopy, an expensive and unpleasant procedure. Carcinoma in situ and other high grade non-muscle-invasive tumors are treated by intravesical administration of BCG or other chemotherapeutic agents, while the indication for muscle-invasive disease is radical cystectomy. Human cells express a family of mitochondrial long non-coding RNAs (ncRNAs). One of these transcripts, the sense mitochondrial ncRNA or SncmtRNA, is expressed in normal proliferating cells and tumor cells but not in non-dividing cells. In addition, normal human proliferating cells express two antisense transcripts, ASncmtRNA-1 and ASncmtRNA-2. Strikingly however, the ASncmtRNAs are down-regulated in tumor cell lines as well as in tumor cells present in different types of human cancer, including BC. Therefore, the differential expression profile of these transcripts allows to detect cancer cells in biopsies and biological fluids. Down-regulation of the ASncmtRNAs seems to be an important hallmark of cancer and, hypothetically, may also represent a general vulnerability of cancer cells. Indeed, knock-down of the ASncmtRNAs using antisense oligonucleotides (ASO) exerts negative effects on cell proliferation and viability of bladder cancer cell lines representing a novel therapeutic strategy for this disease. We discuss recent advances on the use of the mitochondrial ncRNAs as targets for diagnostic and therapeutic protocols of BC and its potential use in the clinic.

AB - Bladder cancer (BC) is a heterogeneous disease with 70% of patients presenting superficial tumours and 30% presenting muscle-invading disease with a high risk of death associated to metastasis. The diagnosis is carried out by urine cytology, whith high specificity but low sensitivity, and cystoscopy, an expensive and unpleasant procedure. Carcinoma in situ and other high grade non-muscle-invasive tumors are treated by intravesical administration of BCG or other chemotherapeutic agents, while the indication for muscle-invasive disease is radical cystectomy. Human cells express a family of mitochondrial long non-coding RNAs (ncRNAs). One of these transcripts, the sense mitochondrial ncRNA or SncmtRNA, is expressed in normal proliferating cells and tumor cells but not in non-dividing cells. In addition, normal human proliferating cells express two antisense transcripts, ASncmtRNA-1 and ASncmtRNA-2. Strikingly however, the ASncmtRNAs are down-regulated in tumor cell lines as well as in tumor cells present in different types of human cancer, including BC. Therefore, the differential expression profile of these transcripts allows to detect cancer cells in biopsies and biological fluids. Down-regulation of the ASncmtRNAs seems to be an important hallmark of cancer and, hypothetically, may also represent a general vulnerability of cancer cells. Indeed, knock-down of the ASncmtRNAs using antisense oligonucleotides (ASO) exerts negative effects on cell proliferation and viability of bladder cancer cell lines representing a novel therapeutic strategy for this disease. We discuss recent advances on the use of the mitochondrial ncRNAs as targets for diagnostic and therapeutic protocols of BC and its potential use in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=84924053309&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 147

EP - 162

JO - International Journal of Cancer Prevention

JF - International Journal of Cancer Prevention

SN - 1554-1134

IS - 2

ER -